---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-080930"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2026-07-07T11:02:35+00:00"
generated_at: "2026-07-07T11:05:05.346642+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tvardi Therapeutics' TTI-109 Phase 1 study confirms prodrug design, improved tolerability, and STAT3 target engagement

## Summary
- TTI-109 rapidly converted to TTI-101 within 2 hours, achieving equivalent plasma exposure at molar-equivalent doses.
- Diarrhea duration with TTI-109 was 0.46 days vs 3.35 days for TTI-101; similar to placebo.
- Pharmacodynamic data showed up to 60% reductions in STAT3-driven immune cell populations (Th17, Tfh, B cells).
- Company plans to advance TTI-109 into STAT3-driven dermatologic and GI diseases, subject to additional funding.
- No serious adverse events; one discontinuation due to transaminitis deemed unlikely related.

## SEC filing metadata
- accession: 0001104659-26-080930
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2026-07-07T11:02:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/0001104659-26-080930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/tm2619879d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-080930
- JSON: https://secwatch.observer/filing/0001104659-26-080930.json
- Plain text: https://secwatch.observer/filing/0001104659-26-080930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.